CSIMarket
 
Design Therapeutics Inc   (DSGN)
Other Ticker:  
 
 
Price: $2.5800 $0.10 4.032%
Day's High: $2.635 Week Perf: -6.18 %
Day's Low: $ 2.48 30 Day Perf: 11.21 %
Volume (M): 261 52 Wk High: $ 8.47
Volume (M$): $ 672 52 Wk Avg: $4.04
Open: $2.48 52 Wk Low: $1.94



 Market Capitalization (Millions $) 144
 Shares Outstanding (Millions) 56
 Employees -
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -72
 Cash Flow (TTM) (Millions $) -15
 Capital Exp. (TTM) (Millions $) 1

Design Therapeutics Inc
Design Therapeutics Inc is a biotechnology company that is focused on developing transformative treatments for serious degenerative conditions that are caused by RNA dysregulation. The company was founded in 2017 by two leading RNA-targeting scientists from Scripps Research, Matthew Disney, PhD, and Adrian Krainer, PhD, along with entrepreneur Jean-Pierre Sommadossi, PhD, who serves as the CEO.

Design Therapeutics is headquartered in San Diego, California and is primarily focused on developing small molecule drugs that specifically target RNA molecules that are malfunctioning in a variety of disease states. RNA is a critical component of gene expression and can play a causal role in many diseases, including neurodegenerative disorders such as amyotrophic lateral sclerosis (ALS) and Parkinson's disease, as well as genetic disorders such as myotonic dystrophy.

The company has a proprietary platform technology called 'DTx RNA Targeting Platform' that enables precision medicine technologies for rigorous target identification and selection followed by the design precise small molecules as potential therapeutics. The platform encompasses in-depth genomics data, small molecule pharmacological properties, and proprietary algorithms for identifying potential RNA targets.

One of the lead programs for Design Therapeutics is in the development of DM1, a small molecule investigational therapy for myotonic dystrophy type 1 (DM1). DM1 is an inherited neuromuscular disorder that affects multiple organs and systems of the body, including the nervous system, heart, and muscle. There is currently no cure for DM1, only supportive therapies for the symptoms. Design Therapeutics is focused on developing a small molecule DM1 drug candidate that selectively inhibits the abnormal protein produced by DM1's genetic mutation.

Furthermore, Design Therapeutics has various collaborations with other biotech companies and institutions. In 2021, it announced a partnership with Regeneron to utilize its precision medicine platform towards discovering RNA-targeting therapeutics.

In summary, Design Therapeutics Inc is a biotechnology company that is focused on developing small molecule drugs that target RNA molecules that are implicated in degenerative diseases, with emphasis on neuromuscular disorders. With a proprietary platform technology and an experienced team, the company aims to bring transformative treatments to the clinic.


   Company Address: 6005 Hidden Valley Road Carlsbad 92011 CA
   Company Phone Number: 293-4900   Stock Exchange / Ticker: NASDAQ DSGN
   


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Design Therapeutics Inc

Design Therapeutics Inc.'s Third Quarter 2023 Numbers Prove They're Leading the Corporate Pack

Exciting Developments in the Stock Market as Design Therapeutics Inc. Shows Promising Results
As the earnings cycle for fiscal July to September 30, 2023, continues, various corporations have been announcing their respective results. Among these, several businesses in the Major Pharmaceutical Preparations industry have caught the attention of market observers. One company, in particular, Design Therapeutics Inc. (DSGN), has made an intriguing revelation in their recent fiscal period.
DSGN recently announced an operating shortfall of $-18.822 million, which, despite being a deficit, is considered a promising result given the lack of better benchmarks. Comparatively, during the same reporting season a year ago, they recorded an operating shortfall of $-19.192 million. This enhancement in their financial performance has brought affirmation and raised eyebrows among market observers.
What is particularly impressive about DSGN's performance is that, despite expanding their revenue streams, they have managed to trim the deficit in the July to September 30, 2023, fiscal period to $-15.789 million. This is a significant improvement from the $-17.704 million recorded in the third quarter of 2022. These figures indicate that DSGN is making strides toward more sustainable financial growth and stability.

Design Therapeutics Inc

Design Therapeutics Inc Faces Challenging Second Quarter, Reports Operating Loss of $22.6 Million

Design Therapeutics Inc is a company in the Major Pharmaceutical Preparations sector that recently reported its second-quarter earnings for 2023. The company experienced an operating loss of $22.596 million during this period, which is an increase from the operating loss of $15.639 million in the second quarter of 2022.
One notable aspect of Design Therapeutics Inc's financial report is the absence of any mention of top-line revenue. This is concerning for analysts, as they wonder if the company will be able to generate significant revenue in the future. It is crucial for Design Therapeutics Inc to establish a profitable business model, especially during challenging periods like the second quarter of 2023, where the deficit widened to $19.937 million.

Design Therapeutics Inc

Design Therapeutics Inc Experiences Setback in the First Quarter of 2023: Major Pharmaceutical Preparations Industry Traces Decline

Design Therapeutics Inc: A Look at the Major Pharmaceutical Preparations Industry Consultant's Interpretation of Their First Quarter 2023 Performance
Design Therapeutics Inc is a rising entity within the Major Pharmaceutical Preparations industry. With a focus on developing targeted small molecule therapies for serious degenerative disorders caused by nucleotide repeat expansions (NREs), they have managed to attract significant attention over the past few years.
However, the first quarter of 2023 has not been kind to the company. As Major Pharmaceutical Preparations industry consultants begin to interpret their performance, Design Therapeutics Inc has reported an operating loss of $-21.651 million, with no specified revenue for the January to March 31, 2023 reporting period.






 




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com